Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG) Versus Alectinib (ALECENSA) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI)

Next Previous
Trial Profile

A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG) Versus Alectinib (ALECENSA) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brigatinib (Primary) ; Alectinib
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ALTA-3
  • Sponsors ARIAD Pharmaceuticals; Takeda

    • Most Recent Events

    • 05 Aug 2019 Planned End Date changed from 4 Sep 2023 to 5 Dec 2022.
    • 05 Aug 2019 Planned End Date changed from 4 Sep 2023 to 5 Dec 2022.
    • 05 Aug 2019 Planned primary completion date changed from 29 Oct 2021 to 4 Dec 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top